<DOC>
	<DOCNO>NCT02006849</DOCNO>
	<brief_summary>The purpose research study determine study drug H.C. Acthar gel slow progression kidney disease . This drug steroid-based medicine few side effect steroid use treatment kidney diseases similar APOL1 nephropathy .</brief_summary>
	<brief_title>ACTH Treatment APOL1- Associated Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Nondiabetic AfricanAmerican two APOL1risk genotype Age ≥21 year BMI &lt; 40 kg/m2 Hemoglobin A1c &lt; 6.5 % eGFR ≥30 ml/min/1.73m2 Historical urine protein : creatinine ratio ≥ 1.0 g/g Strong clinical suspicion APOL1associated nephropathy history biopsy proven focal segmental glomerulosclerosis ( FSGS ) focal global glomerulosclerosis ( FGGS ) Women childbearing potential : negative serum pregnancy test Screening agreement follow medically acceptable form contraception duration Acthar administration 4 week thereafter Diagnosis diabetes mellitus and/or pharmacologic treatment diabetes Medical condition could cause secondary FSGS History sensitivity steroid ( psychosis , steroidinduced diabetes ) Chronic systemic corticosteroid use ( Prednisone equivalent systemic steroid take 4 consecutive week within 6 month prior screen ) . Intraarticular , inhaled , topical steroid exclusion criterion . Contraindication Acthar per package insert : scleroderma , osteoporosis , systemic fungal infection , ocular herpes simplex , recent surgery ( within previous 6 month ) , history presence peptic ulcer ( within 6 month prior Screening ) , adrenal insufficiency hyperfunction . Acute glaucoma diagnose ≤3 month prior Screening Biopsy proven glomerular disease FSGS FGGS Live live attenuate vaccine receive within 1 month prior screening , plan administration enrol study Uncontrolled hypertension ( HTN ) ( ≥ 180/110 mmHg ) frequent admission ( ≥1 admission per 6 month interval ) hypertensive urgency hypertensive emergency Unstable cardiovascular disease : history congestive heart failure ( NYHA Functional Class IIIIV ) ; history dilate cardiomyopathy ejection fraction &lt; 40 % ; follow event within 3 month screen : unstable angina , myocardial infarction , coronary artery bypass graft percutaneous transluminal coronary angioplasty , transient ischemic attack cerebrovascular accident , unstable arrhythmia Uncontrolled volume overload : history moderate severe peripheral edema ; loop diuretic ≥ 120 mg daily furosemide ≥ 3.0 mg daily bumetanide ≥ 150 mg daily ethacrynic acid ≥ 60 mg daily torsemide ; History secondary hypertension ( i.e. , renal artery stenosis , primary aldosteronism pheochromocytoma ) Significant comorbidities ( e.g. , advanced malignancy , advance liver disease ) life expectancy le 1 year Subject expect initiate dialysis within 6 month Previous treatment drug investigate treatment FSGS Known diagnosis Human Immunodeficiency Virus , Hepatitis B , Hepatitis C Known history primary immunodeficiency underlie condition splenectomy predisposes subject infection Systemic hematologic disease ( e.g. , hematologic malignancy , sickle cell anemia , myelodysplastic syndrome ) Current malignancy history malignancy within 5 year screen , exception nonmelanoma skin cancer cervical intraepithelial neoplasia Treatment malignancy ( e.g. , radiation , chemotherapy , hormone therapy , biologics ) within 5 year screen , exception locally excise nonmelanoma skin cancer cervical intraepithelial neoplasia Pregnant breast feeding , might become pregnant study within 4 week end treatment Female reproductive potential willing use highly effective method birth control treatment 4 week end treatment Currently receive systemic antibiotic treatment active infection ; history frequent infection ( one event per 6 month ) History organ transplant Bipolar disorder , Major Depressive Disorder characterize severe depression require hospitalization , history suicidal ideation/attempts Currently enrol another interventional study , less 4 week since end another interventional study ( ) receive investigational agent ( ) Subject disorder , opinion investigator , may compromise ability subject give write informed consent and/or comply require study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>AfricanAmericans</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>ApoL1 gene</keyword>
</DOC>